CL2022001777A1 - 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors - Google Patents

2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Info

Publication number
CL2022001777A1
CL2022001777A1 CL2022001777A CL2022001777A CL2022001777A1 CL 2022001777 A1 CL2022001777 A1 CL 2022001777A1 CL 2022001777 A CL2022001777 A CL 2022001777A CL 2022001777 A CL2022001777 A CL 2022001777A CL 2022001777 A1 CL2022001777 A1 CL 2022001777A1
Authority
CL
Chile
Prior art keywords
inhibitors
methionine adenosyltransferase
oxoquinazoline derivatives
oxoquinazoline
derivatives
Prior art date
Application number
CL2022001777A
Other languages
Spanish (es)
Inventor
Alam Muzaffar
CLEARY Leah
Fleury Melissa
Pei Zhonghua
Steel Richard
Sutton James
E Knox John
E R Newby Zachary
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Priority to CL2022001777A priority Critical patent/CL2022001777A1/en
Publication of CL2022001777A1 publication Critical patent/CL2022001777A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen ciertos derivados de 2-oxoquinazolina de Fórmula (IA): los cuales son inhibidores de la metionina adenosiltransferasa 2A (MAT2A). También, se describen composiciones farmacéuticas que comprenden dichos compuestos y métodos para tratar enfermedades tratables mediante la inhibición de MAT2A, tales como cáncer, incluidos los cánceres caracterizados por una actividad reducida o la ausencia de metiltioadenosina fosforilasa (MTAP).Described herein are certain 2-oxoquinazoline derivatives of Formula (IA): which are inhibitors of methionine adenosyltransferase 2A (MAT2A). Also described are pharmaceutical compositions comprising said compounds and methods for treating diseases treatable by MAT2A inhibition, such as cancer, including cancers characterized by reduced or absent methylthioadenosine phosphorylase (MTAP) activity.

CL2022001777A 2022-06-29 2022-06-29 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors CL2022001777A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2022001777A CL2022001777A1 (en) 2022-06-29 2022-06-29 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2022001777A CL2022001777A1 (en) 2022-06-29 2022-06-29 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Publications (1)

Publication Number Publication Date
CL2022001777A1 true CL2022001777A1 (en) 2023-03-10

Family

ID=85792744

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001777A CL2022001777A1 (en) 2022-06-29 2022-06-29 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Country Status (1)

Country Link
CL (1) CL2022001777A1 (en)

Similar Documents

Publication Publication Date Title
CL2021001508A1 (en) 2-oxoquinazoline derivatives as inhibitors of methionine adenosyltransferase 2a
CO2021017981A2 (en) Heterobicyclic mat2a inhibitors and methods of use for cancer treatment
CL2021001722A1 (en) Aza-heterobicyclic mat2a inhibitors and methods of use in cancer treatment
CL2021001721A1 (en) Aza-heterobicyclic mat2a inhibitors and methods of use to treat cancer
CO2020013968A2 (en) Pladeniolide derivatives as splicing-targeting agents to treat cancer
BR112022000251A2 (en) Macrocyclic Spirocycle Derivatives as mcl-1 Inhibitors
MX2023004373A (en) Methods and compositions for targeted protein degradation.
BR112022026397A2 (en) METHODS FOR TREATTING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES
CO2023005342A2 (en) 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of yap/taz-tead activation for cancer treatment
BR112023000212A2 (en) MACROCYCLIC ETHER CONTAINING INDOL DERIVATIVES AS MCL-1 INHIBITORS
CL2023002633A1 (en) Uracil derivatives as trpa1 inhibitors
CL2022003329A1 (en) Tetrazole derivatives as trpa1 inhibitors
CL2022001777A1 (en) 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
DOP2022000270A (en) TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS
BR112022009142A2 (en) MACROCYCLIC INDOL DERIVATIVES AS MCL-1 INHIBITORS
CL2023000837A1 (en) Tetrazole derivatives as trpa1 inhibitors
CL2023000838A1 (en) Tetrazole derivatives as trpa1 inhibitors
BR112021026170A2 (en) Pharmaceutical composition for tumor treatment??
BR112022024117A2 (en) MACROCYCLIC 7-PYRAZOL-5-YL-INDOL DERIVATIVES AS MCL-1 INHIBITORS
MX2022010299A (en) Macrocyclic indole derivatives as inhibitors of mcl-1.
CL2023002632A1 (en) 3h,4h-thieno[2,3-d]pyrimidin-4-one derivatives as trpa1 inhibitors
MX2023007297A (en) Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1.
BR112022025631A2 (en) N-LINKED MACROCYCLIC 4-(PYRAZOL-5-IL)-INDOLE DERIVATIVES AS MCL-1 INHIBITORS
CL2022001911A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as immunomodulators of pd-11 (sol. div. 202002922).